SMS Pharmaceuticals (NSE:SMSPHARMA, BOM:532815) has received prequalification approval from the World Health Organisation (WHO) for its Unit VII manufacturing facility at Visakhapatnam in Andhra Pradesh, India.
This is expected to help the company increase its presence in the global market for Anti-Retroviral (ARV) active pharmaceutical ingredient, according to a Friday filing to the Indian stock exchanges.
The company's shares were up over 1% in recent trade.